Status:
UNKNOWN
Cellular microRNA Signatures in Multiple Sclerosis
Lead Sponsor:
Institut Pasteur
Collaborating Sponsors:
Höpital La Pitié-Salpêtrière
Conditions:
Multiple Sclerosis, Relapsing-Remitting
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
A limited number of studies on microRNA expression variation in immune cells have been reported in relapsing-remitting multiple sclerosis (RRMS). These studies have been performed mostly on a small sc...
Detailed Description
SEP-MIR is a prospective, single-center, descriptive study. Participants will be recruited among adult patients with RRMS coming for a follow-up consultation in the Neurology Department, Nervous Syst...
Eligibility Criteria
Inclusion
- Caucasian population
- Female and male individuals with an f/m ratio of 2-4/1
- Individuals with RRMS according to the 2010 McDonald criteria for less than 15 years, with EDSS 1-6, in remission or relapse
- Participant's condition compatible with a maximum of 50 ml of blood collection
- Persons affiliated with a social security plan.
Exclusion
- MS treatment with steroidal anti-inflammatory drugs, immunomodulators or immunosuppressants within 2 months prior to blood collection
- Persons with acute and chronic infectious disease, autoimmune/inflammatory disease or cancer other than MS
- Pregnant or lactating women
- Be under guardianship,
- Be deprived of liberty by judicial or administrative decision, or be under legal protection.
Key Trial Info
Start Date :
September 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 15 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05290688
Start Date
September 15 2022
End Date
September 15 2024
Last Update
August 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital La Pitié - Salpêtrière
Paris, France, 75013